JP2017506230A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017506230A5 JP2017506230A5 JP2016550530A JP2016550530A JP2017506230A5 JP 2017506230 A5 JP2017506230 A5 JP 2017506230A5 JP 2016550530 A JP2016550530 A JP 2016550530A JP 2016550530 A JP2016550530 A JP 2016550530A JP 2017506230 A5 JP2017506230 A5 JP 2017506230A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- seq
- domain
- eye
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 210000002845 virion Anatomy 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 208000002780 macular degeneration Diseases 0.000 claims 5
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 claims 4
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 claims 4
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims 2
- 241000702421 Dependoparvovirus Species 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 241001655883 Adeno-associated virus - 1 Species 0.000 claims 1
- 241000202702 Adeno-associated virus - 3 Species 0.000 claims 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 claims 1
- 241001634120 Adeno-associated virus - 5 Species 0.000 claims 1
- 241000972680 Adeno-associated virus - 6 Species 0.000 claims 1
- 241001164823 Adeno-associated virus - 7 Species 0.000 claims 1
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims 1
- 241000649045 Adeno-associated virus 10 Species 0.000 claims 1
- 241000649046 Adeno-associated virus 11 Species 0.000 claims 1
- 241000649047 Adeno-associated virus 12 Species 0.000 claims 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- 206010038848 Retinal detachment Diseases 0.000 claims 1
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 claims 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 239000000710 homodimer Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 230000004410 intraocular pressure Effects 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 210000002301 subretinal fluid Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461936797P | 2014-02-06 | 2014-02-06 | |
| US61/936,797 | 2014-02-06 | ||
| PCT/US2015/014872 WO2015120309A1 (en) | 2014-02-06 | 2015-02-06 | Compositions and methods for treating and preventing macular degeneration |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017506230A JP2017506230A (ja) | 2017-03-02 |
| JP2017506230A5 true JP2017506230A5 (enExample) | 2018-03-15 |
| JP6719381B2 JP6719381B2 (ja) | 2020-07-08 |
Family
ID=52589781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016550530A Active JP6719381B2 (ja) | 2014-02-06 | 2015-02-06 | 黄斑変性を処置し、予防するための組成物および方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20170007719A1 (enExample) |
| EP (1) | EP3102246B1 (enExample) |
| JP (1) | JP6719381B2 (enExample) |
| KR (1) | KR102234695B1 (enExample) |
| CN (3) | CN111068072A (enExample) |
| AU (4) | AU2015213770A1 (enExample) |
| BR (1) | BR112016017817A2 (enExample) |
| CA (1) | CA2938828A1 (enExample) |
| IL (1) | IL247116B (enExample) |
| MX (2) | MX2016010215A (enExample) |
| RU (1) | RU2703145C2 (enExample) |
| SG (1) | SG11201606101WA (enExample) |
| TW (1) | TWI687225B (enExample) |
| WO (1) | WO2015120309A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015120309A1 (en) * | 2014-02-06 | 2015-08-13 | Genzyme Corporation | Compositions and methods for treating and preventing macular degeneration |
| KR101685532B1 (ko) * | 2016-04-26 | 2016-12-13 | 한국프라임제약주식회사 | 혈관내피성장인자 수용체 융합단백질 |
| EP4653536A2 (en) | 2017-03-17 | 2025-11-26 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression |
| KR102205830B1 (ko) * | 2017-10-26 | 2021-01-21 | 주식회사 큐로진생명과학 | 솔루블 VEGFR-1 변이체 cDNA를 함유하는 rAAV를 포함하는 황반변성 치료용 조성물 |
| WO2019161059A1 (en) * | 2018-02-14 | 2019-08-22 | Generation Bio Co. | Non-viral dna vectors and uses thereof for antibody and fusion protein production |
| CN120189533A (zh) * | 2018-10-11 | 2025-06-24 | 分贝治疗公司 | Aav1载体及其用于治疗耳部适应症的用途 |
| CN113952473A (zh) * | 2020-07-21 | 2022-01-21 | 英斯培瑞有限公司 | 用于治疗眼部疾病的组合物和方法 |
| WO2025061000A1 (zh) * | 2023-09-21 | 2025-03-27 | 成都弘基生物科技有限公司 | 一种用于治疗受试者中与血管新生相关的眼病的方法 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| DE10399031I1 (de) | 1987-08-28 | 2004-01-29 | Health Research Inc | Rekombinante Viren. |
| US5693622A (en) | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US6673776B1 (en) | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
| US6214804B1 (en) | 1989-03-21 | 2001-04-10 | Vical Incorporated | Induction of a protective immune response in a mammal by injecting a DNA sequence |
| FR2658432B1 (fr) | 1990-02-22 | 1994-07-01 | Medgenix Group Sa | Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation. |
| WO1992001070A1 (en) | 1990-07-09 | 1992-01-23 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | High efficiency packaging of mutant adeno-associated virus using amber suppressions |
| MY109299A (en) | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| WO1993003769A1 (en) | 1991-08-20 | 1993-03-04 | THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES | Adenovirus mediated transfer of genes to the gastrointestinal tract |
| US5834441A (en) | 1993-09-13 | 1998-11-10 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Adeno-associated viral (AAV) liposomes and methods related thereto |
| WO1996017072A2 (en) | 1994-11-30 | 1996-06-06 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5763270A (en) | 1995-06-07 | 1998-06-09 | Genemedicine, Inc. | Plasmid for delivery of nucleic acids to cells and methods of use |
| JP4051416B2 (ja) | 1995-06-15 | 2008-02-27 | クルーセル ホランド ベスローテン フェンノートシャップ | 遺伝子治療に使用されるヒト組換えアデノウイルス用のパッケージングシステム |
| US6001650A (en) | 1995-08-03 | 1999-12-14 | Avigen, Inc. | High-efficiency wild-type-free AAV helper functions |
| US5622856A (en) | 1995-08-03 | 1997-04-22 | Avigen | High efficiency helper system for AAV vector production |
| US7034009B2 (en) * | 1995-10-26 | 2006-04-25 | Sirna Therapeutics, Inc. | Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R) |
| US6004797A (en) | 1995-11-09 | 1999-12-21 | Avigen, Inc. | Adenovirus helper-free recombinant AAV Virion production |
| US6048551A (en) | 1997-03-27 | 2000-04-11 | Hilfinger; John M. | Microsphere encapsulation of gene transfer vectors |
| US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| US6989264B2 (en) | 1997-09-05 | 2006-01-24 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| US6943153B1 (en) | 1999-03-15 | 2005-09-13 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
| CA2377731A1 (en) | 1999-07-02 | 2001-01-11 | Genentech, Inc. | Fusion peptides comprising a peptide ligand domain and a multimerization domain |
| EP2369002A1 (en) | 1999-08-09 | 2011-09-28 | Targeted Genetics Corporation | Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs |
| AU2001257611A1 (en) | 2000-04-28 | 2001-11-12 | Avigen, Inc. | Polynucleotides for use in recombinant adeno-associated virus virion production |
| ES2256265T3 (es) | 2000-06-01 | 2006-07-16 | University Of North Carolina At Chapel Hill | Vectores de parvovirus duplicados. |
| US6593123B1 (en) | 2000-08-07 | 2003-07-15 | Avigen, Inc. | Large-scale recombinant adeno-associated virus (rAAV) production and purification |
| US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
| NZ535100A (en) | 2002-03-20 | 2008-04-30 | Univ Florida | RAAV vector compositions and methods for the treatment of choroidal neovascularization |
| WO2004079332A2 (en) | 2003-03-04 | 2004-09-16 | National Institute Of Advanced Industrial Science And Technology | Composition and method for increasing efficiency of introduction of target substance into cell |
| PT1625210E (pt) | 2003-05-21 | 2011-03-15 | Genzyme Corp | Métodos para produzir preparações de vírions de aav recombinantes substancialmente livres de capsídeos vazios |
| CN100501049C (zh) * | 2003-08-04 | 2009-06-17 | 邱则有 | 一种现浇砼用空腔模壳构件 |
| CN1997386B (zh) | 2004-07-30 | 2012-05-30 | 瑞泽恩制药公司 | 通过阻断vegf介导的活性来治疗i型糖尿病的方法 |
| EP1804835B9 (en) * | 2004-09-13 | 2010-09-29 | Genzyme Corporation | Multimeric constructs |
| DE602004031786D1 (de) * | 2004-11-26 | 2011-04-21 | Inst Nat Sante Rech Med | Modulierung der retinalen pigmentierten epithel-permeation durch hemmung von vegfr-1 |
| US7765583B2 (en) | 2005-02-28 | 2010-07-27 | France Telecom | System and method for managing virtual user domains |
| US20060234347A1 (en) | 2005-04-13 | 2006-10-19 | Harding Thomas C | Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors |
| US8216575B2 (en) | 2006-03-31 | 2012-07-10 | Chengdu Kanghong Biotechnologies Co., Ltd. | Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains |
| US20090105245A1 (en) * | 2006-12-21 | 2009-04-23 | Bingaman David P | Methods for treating macular edema and ocular angiogenesis using an anti-inflammatory agent and a receptor tyrosine kinase inhibitor |
| EP1995309A1 (en) | 2007-05-21 | 2008-11-26 | Vivalis | Recombinant protein production in avian EBx® cells |
| WO2009042162A2 (en) | 2007-09-25 | 2009-04-02 | Genzyme Corporation | Compositions and methods for inhibiting interleukin pathways |
| US20110053274A1 (en) | 2007-11-30 | 2011-03-03 | Scarab Genomics Llc | Lac expression system |
| BRPI0908496A2 (pt) * | 2008-02-20 | 2019-01-15 | Genzyme Corp | inibição de angiogênese |
| US20100081707A1 (en) | 2008-02-21 | 2010-04-01 | Ali Robin R | Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea |
| WO2010019263A2 (en) | 2008-08-15 | 2010-02-18 | Genzyme Corporation | Soluble flt constructs for treating cancers |
| HUE054940T2 (hu) | 2009-06-16 | 2021-10-28 | Genzyme Corp | Javított eljárások rekombináns AAV-vektorok tisztítására |
| WO2011126808A2 (en) | 2010-03-29 | 2011-10-13 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
| US9102718B2 (en) | 2010-04-30 | 2015-08-11 | Lpath, Inc. | Anti-S1P antibody treatment of patients with ocular disease |
| TWI698240B (zh) * | 2012-05-15 | 2020-07-11 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| CA2909706C (en) | 2013-04-17 | 2023-02-14 | Genzyme Corporation | Use of an il17 inhibitor for treating and preventing macular degeneration |
| WO2015120309A1 (en) | 2014-02-06 | 2015-08-13 | Genzyme Corporation | Compositions and methods for treating and preventing macular degeneration |
-
2015
- 2015-02-06 WO PCT/US2015/014872 patent/WO2015120309A1/en not_active Ceased
- 2015-02-06 CN CN201911282594.9A patent/CN111068072A/zh active Pending
- 2015-02-06 SG SG11201606101WA patent/SG11201606101WA/en unknown
- 2015-02-06 CN CN202510316733.4A patent/CN120131999A/zh active Pending
- 2015-02-06 US US15/113,720 patent/US20170007719A1/en not_active Abandoned
- 2015-02-06 KR KR1020167024302A patent/KR102234695B1/ko active Active
- 2015-02-06 MX MX2016010215A patent/MX2016010215A/es unknown
- 2015-02-06 CA CA2938828A patent/CA2938828A1/en active Pending
- 2015-02-06 EP EP15706595.4A patent/EP3102246B1/en active Active
- 2015-02-06 CN CN201580017612.4A patent/CN106163573A/zh active Pending
- 2015-02-06 TW TW104104067A patent/TWI687225B/zh active
- 2015-02-06 RU RU2016135771A patent/RU2703145C2/ru active
- 2015-02-06 JP JP2016550530A patent/JP6719381B2/ja active Active
- 2015-02-06 AU AU2015213770A patent/AU2015213770A1/en not_active Abandoned
- 2015-02-06 BR BR112016017817A patent/BR112016017817A2/pt not_active Application Discontinuation
-
2016
- 2016-08-04 IL IL247116A patent/IL247116B/en active IP Right Grant
- 2016-08-05 MX MX2023011453A patent/MX2023011453A/es unknown
-
2019
- 2019-05-15 AU AU2019203413A patent/AU2019203413B2/en active Active
-
2021
- 2021-10-15 AU AU2021250986A patent/AU2021250986B2/en active Active
-
2022
- 2022-02-25 US US17/681,468 patent/US12483047B2/en active Active
-
2025
- 2025-05-05 AU AU2025203206A patent/AU2025203206A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017506230A5 (enExample) | ||
| RU2016135771A (ru) | Композиции и способы лечения и предотвращения дегенерации желтого пятна | |
| JP2020528734A5 (enExample) | ||
| US20210324343A1 (en) | Recombinant adeno-associated virus particle purification comprising an affinity purification step | |
| JP2019518427A5 (enExample) | ||
| RU2014146159A (ru) | Композиция и способы высокоэффективного переноса генов с помощью вариантов капсида aav | |
| IL273261B1 (en) | Adeno-associated virus variant capsids and methods of use thereof | |
| AU2019250249A1 (en) | Promoters, expression cassettes, vectors, kits, and methods for the treatment of achromatopsia and other diseases | |
| AU2017257169B2 (en) | Evasion of neutralizing antibodies by a recombinant adeno-associated virus | |
| JP2017518271A5 (enExample) | ||
| JP7410522B2 (ja) | 抗ｆａｍ１９ａ５抗体のアデノ関連ウイルス（ａａｖ）伝達 | |
| CN110650733A (zh) | 经过修饰的aav衣壳和其用途 | |
| JP2018508519A5 (enExample) | ||
| JP2021500071A5 (enExample) | ||
| RU2017125234A (ru) | Конструкции нуклеиновой кислоты и векторы для генотерапии для применения для лечения болезни вильсона и других состояний | |
| JP2017512466A5 (enExample) | ||
| HRP20240580T1 (hr) | ISPORUKA ADENO-POVEZANIM VIRUSNIM VEKTOROM β-SARKOGLIKANA I MIKRORNA-29 I LIJEČENJE MIŠIĆNE DISTROFIJE | |
| JP2019511570A5 (enExample) | ||
| RU2013151885A (ru) | Вирионы аденоассоциированного вируса с вариантным капсидом и способы их использования | |
| HRP20201831T1 (hr) | Optimizirani promoter rpe65 i kodirajuće sekvence | |
| JP2018526003A (ja) | イヌの癌を治療するためのキメラａａｖ−抗ｖｅｇｆ | |
| JP2018510620A5 (enExample) | ||
| JP2017529395A5 (enExample) | ||
| HRP20241483T1 (hr) | Sastavi i postupci za liječenje poremećaja mrežnice | |
| JP2024509251A (ja) | デュアルウイルスベクター系による抗体送達 |